RPhLink - Fosamax - Dyrenium

RPhLink.com The Pharmaceutical Care Network!

RPhLink.com The Pharmaceutical Care Network!

RPhLink.com The Pharmaceutical care Network!

From WellSpring Pharmaceutical

Important Notice Concerning DYRENIUM ® and DIBENZTLINE ® and the Medicaid Program

WellSpring Pharmaceutical Corporattion ("WellSpring") owns the prescription drugs DYRENIUM® and DIBENZYLINE®. As you may know, WellSpring does not particiapate as a supplier in any state Medicaid program.

A distributing development has come to our attention in connection with prescriptions for DYRENIUM® and DIBENZYLINE® presented by Medicaid beneficiaries. We understand that some pharmacies have been using the nationsl drug code (NDC) number assigned to another pharmaceutical company for the purpose of obtaining reimbursement from the Medicaid program for these particular medications, even though the drugs were labled as WellSpring pharmacueticals. This activity is causing WellSpring to suffer financial damage, and may subject a pharmacy engaging in such activity to liability under federal and state laws dealing with the Medicaid program, flase claim submission and a variety of other issues.

Accordingly, this is to advise all pharmacies that are improperly billing Medicaid to cease and desist immediatley from using incorrect NDC numbers in submitting claims for DYRENIUM® and DIBENZYLINE® to the Medicaid program. Pharmacies must use the NDC number that is on the label of the prodct that is being dispensed to the Medicaid patient. Although we hope it will be unnecessary, we are prepared to take immediate and definitive steps to protect WellSpring's rights and interests should this conduct continue.

We would like you to know that our decision to opt out of the Medicaid program was a difficult one, based on peculiar mechanics in the law that would require WellSpring to pay Medicaid a substantional amount of money in excess of the paymenr that we would receive from Medicaid for the sale of these medications.

If your pharmacy has not been billing improperly Medicaid for DYRENIUM® and DIBENZYLINE® we apologize for any confusion that his letter may have caused. On the other hand, if your pharmacy has been using incorrect NDC numbers in connection with bilings for these medications, we trust that you can appreciate our situation and we thank you for your anticipated cooperation.

Wendy M. Shusko, VP Finance

Back to previous page

RPhLink.com The #1 Link for Pharmacists and Pharmacy Techs

Fosamax

POMONA, N.Y., Sept 5 -From Barr Laboratories, Inc. (NYSE:BRL) today announced that it has initiated a challenge of the patents protecting Merck & Co., Inc.'s Fosamax (alendronate Sodium) Tablets, USP 70mg from generic competition. Fosamax Tablets, USP 70mg has current annual sales of approximately $762.7 million. The company indicated that it is not the first to file an Abbreviated New Drug Application (ANDA) with the U.S. Food & Drug Administration (FDA) for the 70mg tablet product.

Fosamax(R) is indicated for the treatment and prevention of osteoporosis in postmenopausal women and for the treatment of Paget's disease of bone in men and women.

"A successful challenge of the patents protecting Fosamax could provide patients suffering with osteoporosis a more affordable version of this critical therapy years earlier than might have otherwise occurred," said Bruce L. Downey, Barr's Chairman and CEO. "As America ages, and consumers seek medicines to enhance the quality of life, the opportunity to bring a generic version of Alendronate to consumers further demonstrates the value of the patent challenge process and the potential value it may create for consumers."

Barr filed an ANDA for alendronate sodium tablets with the U.S. Food and Drug Administration (FDA) in June 2001, and received notification of the application's acceptance for filing in July. Following receipt of notice from FDA, Barr notified Merck & Co., Inc. On August 31, 2001, Merck filed suit in U.S. District Court for the District of Delaware to prevent Barr from proceeding with the commercialization of this product. This action formally initiated the patent challenge process.

Barr recently announced that the Company has entered into a merger agreement with Duramed Pharmaceuticals, Inc. (Nasdaq: DRMD), a developer, manufacturer and marketer of prescription drug products, focusing on women's health and the hormone replacement therapy markets. The transaction is subject to customary approvals and other conditions, and is expected to close early in Barr's second fiscal 2002 quarter.

Barr Laboratories, Inc. is a specialty pharmaceutical company engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals.

Safe Harbor Statement: To the extent that any statements made in this release contain information that is not historical, these statements are essentially forward-looking. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include: the timing and outcome of legal proceedings; including Eli Lily's appeal to the Supreme Court, the difficulty of predicting the timing of U.S. Food and Drug Administration ("FDA") approvals; the difficulty in predicting the timing and outcome of FDA decisions on patent challenges; market and customer acceptance and demand for new pharmaceutical products; ability to market proprietary products; the impact of competitive products and pricing; timing and success of product development and launch; availability of raw materials; the regulatory environment; fluctuations in operating results; and, other risks detailed from time-to-time in the Company's filings with the Securities and of words such as "expects," "plans," "will," "believes," "estimates," "intends," "may," and other words of similar meaning. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update any forward-looking statements.

Front Page | Link to the lounge | Pharmacy News

© 2000 RPhLink.com The Pharmaceutical Care Network! is designed and published by RPhLink. Inc. All Rights Reserved. RPhLink.com is designed by RPhs for Pharmacists & Pharmacy Techs. For information use only! Disclaimer.

RPhLink.com A Great Link for the IPhBOs (Independent Pharmacy Business Owners)

Nicomide

Contact Information:

For more information on Nicomide, contact Sirius Laboratories Customer Service at

(866)292-2108.

Who we are:

The mission of Sirius Laboratories is to provide unique prescription products for dermatologists and their patients.

Link to the lounge

RPhLink.com The Pharmaceutical care Network!

Dentaplex From Collagenex Pharmaceuticals

The Dietary Supplement for Optimal Oral Health

Developed in conjunction with dentists, Dentaplex is specifically formulated to help patients obtain the nutrients they need for proper growth, protection, and overall health of oral structures and tissues.
Dentaplex contains a unique blend of dental-specific micronutrients:

- essential vitamins A, C, D, E

- essential B complex vitamins

- calcium, magnesium, zinc, selenium, copper, molybdenum, and vanadium

Dentaplex is easy, convenient, and economical to use

- competitively priced

- available without a prescription

Dentaplex will be heavily promoted with a strong, highly visible marketing program:

- CollaGenex Pharmaceuticals national dental sales team

- journal ads

- direct mail

- exhibits at major dental events

Introducing New Dentaplex- The Dietary Supplement Specifically Formulated to Help Maintain Healthy Teeth and Gums

CollaGenex Pharmaceuticals Inc., a leader in the field of oral health, is pleased to introduce new Dentaplex, a new nutritional supplement designed specifically to help maintain healthy teeth and gums. Developed in conjunction with dentists, Dentaplex is specifically formulated to contain the nutrients necessary for proper growth, and overall health of oral structures and tissues.

A unique blend of micronutrients-including the C-Complex of calcium, vitamin C, and carotene-that have been associated with maintaining oral health.

Dentaplex contained essential vitamins A, C, D, E, and B complex, as well as the minerals calcium, magnesium, zinc, selenium, copper, molybdenum, and vanadium.

Convenlent and economical to use

Dentaplex is reasonably priced and available without a prescription.

Dentaplex will be heavily promoted with a strong, highly marketing program including:

* CollaGenex Pharmaceuticals national dental sales team * Direct mail

* Journal advertisements * Exhibits at major dental events

We encourage you to recommend Dentaplex, the nutritional supplement specifically designed to help maintain oral health.

PS. Order now by contacting your wholesaler or category manager. The product code for Dentaplex is 428-50.

For product information, please call CollaGenex Pharmaceuticals Professional & Dental Affairs toll free at 1-888-339-5678 or visit our website at www.collagenex.com.

Back to previous page

RPhLink.com The Pharmaceutical Care Network! New SKUS from Alpharma

June 2002

From Abbott

Dear Pharmacist:

I am writing to ensure you have the most up-to-date information about Abbott's prescription obesity medication, Meridia® ( sibutramine HCl monohydrate) C-IV capsules. Attached is a press release detailing the outcome of a recent meeting of Europe's Committee for Proprietary Medicinal Products (CPMP). I would like to highlight the key points:

The CPMP issued a positive opinion reaffirming the favorable risk/benefit profile of sibutramine capsules for the treatment of obesity. The CPMP's conclusion reconfirms those of Abbott and leading experts in the treatment of obesity. It is consistent with the conclusions made by the U.S. Food and Drug Administration (FDA) in 1997 during the new drug approval process. The CPMP's conclusions were supported by an extensive analysis of data provided by Abbott that included more than 100 clinical studies of sibutramine in 12,000 obese patients, dating back to 1989.

The CPMP review, conducted on behalf of the 15 European Community member states, represents one of the most extensive reviews of sibutramine data to date. Sibutramine has been prescribed to more than 8.5 million people in over 70 countries. Meridia is the most extensively studied prescription medication currently available for the treatment of obesity.

Meridia is indicated for the management of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a reduced calorie diet. Meridia is recommended for obese patients with an initial body mass index > 30 kg/m², or > 27 kg/m² in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia).

Meridia is contraindicated in patients receiving monoamine oxidase inhibitors (MAOIs), patients with anorexia nervosa, those with hypersensitivity to sibutramine or any ingredients of Meridia, and those taking other centrally acting appetite-suppressant drugs.

Meridia substantially increases blood pressure in some patients. Regular monitoring of blood pressure is required when prescribing Meridia. For patients who experience a sustained increase in blood pressure or pulse rate while receiving Meridia, either a dose reduction or discontinuation should be considered.

Meridia should not be used in patients with a history of coronary artery disease arrhythmia, congestive heart failure, or stroke. Meridia should not be used in patients with uncontrolled or poorly controlled hypertension, severe hepatic dysfunction, or severe renal impairment. Meridia should be used with caution in patients with narrow-angle glaucoma or a history of seizures.

Meridia® (sibutramine HCl monohydrate) C-IV capsules inhibits semitonic reawake; in general, it should not be administered with other semitone agents. However, if such a combination is clinically indicated, appropriate observation of the patient is warranted. Women who are pregnant of planning to become pregnant or who are breast-feeding their infant should not use Meridia.

Most common adverse events include headache (30%), dry mouth (17%), anorexia (13%), constipation (12%), and insomnia (11%).

Should you have any questions regarding Meridia, please see the enclosed Full Prescribing Information, or visit www.Meridia.net, or contact our Medical Information Department at (800) 633-9110.

Sincerely,

Cheryl Renz, M.D. Medical Director and Global Project Head for Sibutramine Abbott Laboratories

Meridia® News Updates | more news | discussions | front page

From Alpharma. Did you Know?

Alpharma's family of sterile respiratory products has grown. It now includes the products you and your customers need most-Albuterol Sulfate 0.083%, Cromolyn Sodium 20mg/2ml, and Ipratropium Bromide 0.02% inhalation solutions.

This newly expanded line means you have another option for quality respiratory products that are: manufactured and filled in a sterile environment in compliance with the most recent FDA guidelines; packaged in pre-mixed, single-use vials for dosing convenience and to maintain product integrity; boxed in quantities suited to varied operations, such as monthly maintenance programs.It also means you can turn to the nation's leading manufacturer of liquid and topical generic pharmaceuticals for another essential line of generics.

Giving you a new choice for a comprehensive respiratory product line is the latest way Alpharma supports your business's profitability. Look to Alpharma for generic medicines...extraordinary solutions. For more information check the website at www.alpharmauspd.com

RPhLink.com The Pharmaceutical Care Network

Link to previous page

RPhLink.com The Pharmaceutical Care Network!

Centocor Presents Medications for Use in the Intervention and Management of Chest Pain.

Today, new healthcare services, improved clinical outcomes and progressive technology in the intervention and management of chest pain are leading to changes within the hospital setting. With this, the clinical pharmacist is becoming ever more instrumental in driving the patient care delivery process.

Centocor is excited about the opportunity to work with you to improve patient care through the use of RETAVASE (reteplace, ReoPro (abciximab) and FRAGMIN (dalteparin sodium injection). Centocor is also dedicated in helping you optimize your resources in your quest to provide cost-effective, integrated, high-quality care in today's clinical environment.

If you are interested in learning more about Centocor's products or for full prescribing information, visit one of Centocor's websites at www.retavase.com, www.reopro.com, or www.centocor.com.

Back to previous page | Drug News Updates

RPhLink.com

Mead Johnson to discontinue Enfamil Natalins RxNDC# 0087-070249

December 9, 1999

We want to make you aware of a decision that we have made todiscontinue Enfamil Natalins Rx. our presciption prenatal vitamin supplement.

As you are probably aware, we have been facing increased competition from generic products in this category for several years. The unique Comfort Core technology prevented us from matching the lower prices of the generic products, and also created several challenges in the production of Enfamil Natalins Rx. These challenges have too frequently made it difficult for us to maintain the high standards you expect from us, and we demand of ourselves, in the areas of product supply and order fulfillment.

Health Care Professionals are being notified of this decision, and should discontinue writing new scrips for Enfamil Natalins Rx immediately. In the meantime, you should continue to stock any remaining inventories to meet refill needs of Enfamil Natalins Rx users during this transition period.

We first introduced Natalins in 1952 so this has been a very difficult decision for us. We appreciate your understanding and welcome your comments.

Should you have any questions, please contact us at 1-800-426-7876 (select option 7).

Sandy MacPherson

Senior Vice President and General Manager

Mead Johnson Nutritionals

RPhLink.com The Pharmaceutical Care Network!

Back to previous page

More News from Kinray| Previous News | Front Page!

General Pharmacy Classified | Pharmacy Antiques | Pharmacy Collectibles | Pharmacy Archives